UBT251 is an investigational once-weekly GLP-1, GIP and glucagon triple agonist from The United Bio-Technology (Hengqin), a subsidiary of China's United Laboratories, licensed to Novo Nordisk outside Greater China in March 2025. Its best Phase 2 arm lost 19.7% of body weight at 24 weeks in 205 Chinese adults. Retatrutide's 12 mg arm lost 17.5% at 24 weeks in its own Phase 2, then 28.3% at 80 weeks in the 2,339-person TRIUMPH-1. No trial has compared the two. UBT251's structure is unpublished, and our Janoshik and Kovera mirrors hold zero UBT251 test records.
What is UBT251, and what has been published?
UBT251 is a real drug candidate with 24 weeks of Phase 2 data and no approval date. Its best 24-week result edges retatrutide's, but retatrutide has 80-week Phase 3 results in thousands of people and UBT251 does not.
| UBT251 | Retatrutide | |
|---|---|---|
| Targets | GLP-1, GIP, glucagon | GLP-1, GIP, glucagon |
| Developer | The United Bio-Technology (Hengqin), part of The United Laboratories (TUL); Novo Nordisk holds rights outside Greater China | Eli Lilly |
| Stage on 10 October 2026 | Phase 2 published; Chinese Phase 3 running | Phase 3 (TRIUMPH) results reported |
| Longest published data | 24 weeks | 80 weeks |
| Best 24-week weight loss | 19.7% (4 mg arm, 205 Chinese adults, mean 92.2 kg) | 17.5% (12 mg, 338 US adults, mean 107.7 kg) |
| Structure published | No | Yes |
| Public lab records in our mirrors | 0 | 68 Janoshik reports; hundreds of Kovera certificates |
The 24-week figures come from different trials, populations and analyses, and no trial has compared the two drugs.
Who developed UBT251?
The United Bio-Technology (Hengqin) Co., a wholly owned subsidiary of TUL, developed it. On 24 March 2025 Novo Nordisk licensed exclusive rights outside mainland China, Hong Kong, Macau and Taiwan, for $200 million upfront and up to $1.8 billion in milestones. AdisInsight lists the Novo code as NN-9559.
The published record:
- Phase 1a/1b, China. Weekly 1, 3 and 6 mg for 12 weeks produced mean losses of 8.96 to 13.48 kg against a 1.57 kg gain on placebo (Diabetes, Obesity and Metabolism, September 2026). The March 2025 release put the top-dose loss among completers at 15.1%, against a 1.5% gain on placebo.
- Phase 2 in obesity, China, 205 adults, mean BMI 33.1, no diabetes. Least-squares mean loss at 24 weeks was 13.6% (2 mg), 16.2% and 19.7% (two 4 mg arms with different starting doses) and 18.7% (6 mg), against 2.0% on placebo (ADA 2026 abstract 3090-LB, 5 June 2026). The full paper appeared in Cell Metabolism on 7 October 2026, with a placebo-adjusted best result of 17.7%.
- Phase 2 in type 2 diabetes, China, 211 adults. HbA1c fell up to 2.16 points from 8.12%, against 1.77 on semaglutide 1 mg and 0.66 on placebo. Weight fell up to 9.8% against 4.8% on semaglutide (TUL and Novo Nordisk, 25 March 2026).
The 19.7% headline came from a 4 mg arm; the 6 mg arm produced 18.7%. The companies' 24 February 2026 release called 19.7% the "highest mean weight loss observed" without naming the arm.
ClinicalTrials.gov listed 14 UBT251 studies on 10 October 2026. Novo's global obesity trial (NCT07395687, 333 people in the US and Canada), called Phase 1b/2a by the companies and Phase 2 by the registry, shows primary completion in January 2027. TUL's Chinese Phase 3 trials in obesity and type 2 diabetes list completion between September 2027 and February 2028.
UBT251 vs retatrutide: how do the trials compare?
| Program | Trial | Phase | Population | n | Weeks | Top result | Placebo |
|---|---|---|---|---|---|---|---|
| UBT251 | Phase 1b | 1b | China, overweight/obesity | 36 | 12 | −15.1% (completers, top group) | +1.5% (March 2025 release; +1.57 kg in the paper) |
| UBT251 | NCT07177469 | 2 | China, BMI 33.1, no diabetes | 205 | 24 | −19.7% (4 mg arm) | −2.0% |
| UBT251 | NCT07163624 | 2 | China, type 2 diabetes | 211 | 24 | −9.8%; HbA1c −2.16 | −1.4% |
| Retatrutide | Phase 2, NEJM 2023 | 2 | US, mean 107.7 kg, no diabetes | 338 | 24 | −17.5% (12 mg) | −1.6% |
| Retatrutide | Phase 2, NEJM 2023 | 2 | same | 338 | 48 | −24.2% (12 mg) | −2.1% |
| Retatrutide | TRIUMPH-1 | 3 | obesity, no diabetes | 2,339 | 80 | −28.3% (Lilly) / −25.0% (NEJM) | see TRIUMPH page |
| Retatrutide | TRIUMPH-2 | 3 | obesity + type 2 diabetes | 1,152 | 80 | −20.8% / −18.8% | −4.0% / −5.1% |
Sources by row: TUL and Novo Nordisk 24 March 2025; Cell Metabolism, 7 October 2026 and the ADA abstract; TUL and Novo Nordisk 25 March 2026; NEJM 2023 for both Phase 2 rows; our TRIUMPH results page for the Phase 3 rows.
At 24 weeks UBT251's best arm sits 2.2 points above retatrutide 12 mg. Against placebo the gap is similar: 17.7% for UBT251 and about 15.9% for retatrutide, our subtraction of the published means. Three things weaken the comparison:
- Population. UBT251 enrolled Chinese adults averaging 34 years and 92.2 kg; retatrutide's Phase 2 started at 107.7 kg. Percentage loss depends on starting weight.
- Duration. Retatrutide 12 mg went from 17.5% at week 24 to 24.2% at week 48. No one has published UBT251 data past week 24.
- Safety data. Retatrutide's Phase 2 reported dose-dependent heart-rate increases that peaked at 24 weeks. The UBT251 abstracts we read describe side effects only as mostly mild-to-moderate gastrointestinal events, with no heart-rate or discontinuation figures. Researchers link glucagon receptor activity to heart-rate effects in this class, so the gap matters.
The diabetes trial gives one true head-to-head: UBT251's best arm beat semaglutide 1 mg on HbA1c (2.16 against 1.77 points) and weight (9.8% against 4.8%). The release gave no statistical test, and 1 mg is the diabetes dose of semaglutide, not tirzepatide or retatrutide. Our retatrutide vs tirzepatide page covers the Lilly drugs.
What is Reddit claiming about UBT251?
Four threads posted on 7 and 8 October 2026 drew about 127 comments by 10 October. The most-shared, "UBT251: The Triple Agonist Positioned to Succeed Retatrutide," appeared in r/BiohackingU and r/BodyHackGuide.
| Claim in the essay | What the record shows |
|---|---|
| Phase 2 results "exceed retatrutide's at the same timepoint" | Numerically true at 24 weeks (19.7% against 17.5%), across different trials and populations. |
| "Reaches its effect at a lower dose" | Milligrams do not compare across different molecules. |
| "Appears to carry a lighter glucagon component" | We found no published receptor-potency data. The structure is undisclosed. |
| "No enforcement campaign against its supply" | No legitimate supply exists to enforce against. Novo Nordisk holds the rights outside Greater China. |
In the r/GLP1ResearchTalk question thread, "about to take Reta's crown," most of the 70 comments said no, for supply reasons: "Reta will continue to be easy to get from china," read the top reply. A fourth thread summarised the Phase 2 data with sources and caveats and drew 9 comments.
Is the UBT251 hype being seeded?
- One essay, two subreddits. The same essay of about 15,000 characters went up at 13:47 and 23:26 UTC on 7 October. On 10 October our Reddit reader returned no profile for the posting account; we do not know why.
- A companion question. The "crown" thread went up at 23:21 UTC, five minutes before the second essay post, from an account created 76 days earlier with 5 comment karma.
- Commenters called it out. "That's a really long ad lmao," read one reply. "This feels like a covert marketing campaign for UBT251," read another.
- No search demand. US Google Trends showed "ubt251", "ubt 251" and "ubt-251" at or near zero for the previous 90 days, including 7 and 8 October.
We found no vendor link in the part of the essay we could retrieve, which was only its opening section. The timing fits a known pattern: retatrutide sells under code names like "GLP-3 RT", storefronts listed eloralintide by early October, and Lilly filed five more retatrutide suits on 8 October (lawsuit tracker).
Is anyone selling UBT251, and has any lab tested it?
On 10 October 2026 we found two listings, which we are not linking. A US-facing RUO storefront showed a "UBT-251" page marked out of stock, priced at $0.00 down from $200, with a second code, "NN8448", that does not match AdisInsight's NN-9559. A Chinese manufacturer listed UBT251 as a "custom" item in 10-vial kits. Aggregator pages also use the name "Vistrutide", which one independent evidence ledger found in no WHO INN list, trial protocol or registry.
Our lab data holds zero UBT251 records: none in our Janoshik mirror (337 readable reports, 364 indexed, through 30 June 2026) or our Kovera mirror (1,828 certificates, snapshot 1 August 2026), searching UBT251, UBT-251, UBT 251, NN8448 and Vistrutide.
A certificate would prove less than usual. Labs confirm identity by matching a sample's mass to the known molecule, and none of the papers, registry entries or releases we read disclose UBT251's sequence or mass. A "UBT251" certificate can report purity but cannot show the vial holds the trial molecule. If you see one, resolve it on the lab's own site with our COA verifier and ask which reference standard the lab used for identity.
What we read
- TUL and Novo Nordisk releases of 24 March 2025, 24 February 2026 and 25 March 2026.
- The Cell Metabolism Phase 2 abstract (7 October 2026), ADA 2026 abstract 3090-LB, and the Phase 1a/1b abstract in Diabetes, Obesity and Metabolism.
- All 14 UBT251 entries on ClinicalTrials.gov, read 10 October 2026.
- The retatrutide Phase 2 paper in NEJM and our TRIUMPH coverage.
- Four Reddit threads from 7 and 8 October 2026 with their comments, plus public account age and karma.
- Two storefront pages listing UBT251, read 10 October 2026.
What we did not read
The full Cell Metabolism paper, including its safety tables. The Reddit essay past its opening section. Any certificate for a vial sold as UBT251, because we found none. We did not test any UBT251 material.
Sources
- TUL and Novo Nordisk, license agreement, 24 March 2025
- TUL and Novo Nordisk, Phase 2 obesity topline, 24 February 2026
- TUL and Novo Nordisk, Phase 2 type 2 diabetes topline, 25 March 2026
- Cell Metabolism, UBT251 Phase 2 in overweight or obesity, 7 October 2026
- Diabetes, ADA late-breaking abstract 3090-LB, 5 June 2026
- Diabetes, Obesity and Metabolism, UBT251 Phase 1a/1b, September 2026
- ClinicalTrials.gov, UBT251 studies, read 10 October 2026
- Reuters, UBT251 Phase 2 results, 24 February 2026
- AdisInsight, UBT 251 drug profile
- Retatrutide Phase 2, NEJM, 2023
- Vialog, Vistrutide (UBT251) evidence ledger
- r/BiohackingU, UBT251 essay, 7 October 2026
- r/BodyHackGuide, same essay, 7 October 2026
- r/GLP1ResearchTalk, "Reta's crown" thread, 7 October 2026
- r/GLP1ResearchTalk, Phase 2 summary thread, 8 October 2026
- Internal: retatrutide, TRIUMPH results, eloralintide vs retatrutide, GLP-3 RT code name, Lilly lawsuits
Frequently asked
What is UBT251?
UBT251 is an investigational long-acting peptide that activates the GLP-1, GIP and glucagon receptors, the same three targets as retatrutide. The United Bio-Technology (Hengqin), part of Hong Kong-listed United Laboratories, developed it. Novo Nordisk licensed rights outside mainland China, Hong Kong, Macau and Taiwan in March 2025 for $200 million upfront. It is not approved anywhere.
Is UBT251 better than retatrutide?
Nobody knows yet. At 24 weeks, UBT251's best arm lost 19.7% in Chinese adults with a mean starting weight of 92.2 kg. Retatrutide 12 mg lost 17.5% at 24 weeks in a heavier US population. Different trials, populations and analyses. Retatrutide also has 80-week Phase 3 data; UBT251 has nothing past 24 weeks.
Who owns UBT251, Novo Nordisk or United Laboratories?
Both, by territory. United Laboratories' subsidiary keeps rights in mainland China, Hong Kong, Macau and Taiwan and runs the Chinese trials, including Phase 3 studies registered in 2026. Novo Nordisk holds exclusive rights everywhere else and runs the global trials, the first of which is due to complete in January 2027.
When will UBT251 be approved?
No company has given a date. Chinese Phase 3 trials in obesity and type 2 diabetes list primary completion dates in 2027 and 2028 on ClinicalTrials.gov. Novo's global obesity Phase 2 lists January 2027. Any US approval would need Phase 3 trials that had not started as of 10 October 2026.
Can you buy UBT251 as a research peptide?
A few storefronts list it. On 10 October 2026 we found one US-facing page marked out of stock and one Chinese manufacturer offering it as a custom order. We found zero UBT251 records in our Janoshik and Kovera mirrors. Because no structure has been published, no lab can confirm a vial contains the trial molecule.
Is the UBT251 hype on Reddit real?
The trial data is real. The "next retatrutide" framing came from four threads posted within 31 hours, two carrying the same long essay from one account and one from an account 76 days old. Commenters called it an ad. We cannot prove a vendor wrote it; the pattern matches seeding.